Loading organizations...
§ Private Profile · Mountain View, CA, USA
Diagnostics company that developed a non-invasive, saliva-based platform for scalable detection of cancer and other diseases.
AEENA Dx is a biotechnology company based in Mountain View, California, that develops a noninvasive saliva platform for the scalable detection of cancer and other diseases. The organization originally spun out of Prime Genomics, expanding its initial clinical focus on a proprietary breast cancer test to encompass broader diagnostics for multiple healthcare markets. The enterprise attracted strategic backing from healthcare investors including DigitalDx Ventures, whose managing partner Michele Colucci served as board chair alongside former Myriad Genetics executive Jerry Lanchbury. To expand its point of care and over the counter diagnostic capabilities across the medical sector, the firm eventually executed a corporate merger with NOWDx to form the combined entity NOWDiagnostics under the leadership of chief executive officer Rob Weigle. The diagnostic technology company was originally established by its co-founder and chief technology officer Shivani Nautiyal.
AEENA Dx has raised $48K across 1 funding round.
AEENA Dx has raised $48K in total across 1 funding round.
AEENA Dx was a Silicon Valley-based diagnostics company specializing in innovative salivary testing platforms, particularly for non-invasive cancer detection such as breast cancer proof-of-concept, alongside offerings in genomics, Pap tests, and pathology.[2][4] It served healthcare providers and patients by addressing needs in point-of-care (POC), over-the-counter (OTC), and at-home diagnostics, solving problems like accessible, scalable testing for infectious diseases, women's health, cardiac markers, drugs of abuse, and cancer through its salivary collection device and diagnostic technology.[1][4] The company merged with NOWDx in a pivotal deal, forming NOWDiagnostics (NOWDx), which combines AEENA Dx's salivary cancer platform with NOWDx's blood/saliva collection and quantitative reader tech, positioning the entity to target the $100 billion global diagnostics market with production capacity exceeding 2 million tests monthly.[1]
Post-merger, growth momentum centers on commercializing launched tests (e.g., for syphilis and strep) and advancing a robust R&D pipeline, led by AEENA Dx's leadership integrating into NOWDx's operations in Springdale, Arkansas.[1]
AEENA Dx emerged as a Silicon Valley startup focused on groundbreaking diagnostics, co-founded by CTO Shivani Nautiyal and CSO Kevin Clark, with CEO Rob Weigle at the helm pre-merger.[1][4] The idea stemmed from developing a "game-changing" salivary cancer diagnostic platform and collection device, starting with proof-of-concept for breast cancer detection and expanding to other critical areas like women's health and infectious diseases.[1][2] Early traction included establishing this non-invasive tech foundation, attracting board members like Michele Colucci and investors tracked in specialized databases, humanizing its mission to democratize healthcare access.[1][5] A pivotal moment arrived with the merger announcement with NOWDx, blending AEENA Dx's innovation with manufacturing scale to accelerate global impact.[1]
AEENA Dx rode the wave of non-invasive, POC diagnostics trends, capitalizing on post-pandemic demand for at-home and rapid testing amid a $100 billion market fueled by aging populations, chronic disease prevalence, and healthcare accessibility gaps.[1] Timing was ideal as salivary tech addressed limitations in invasive sampling, aligning with shifts toward scalable, quantitative readers for infectious, oncologic, and women's health needs.[1][2][4] Market forces like manufacturing scale (2M+ tests/month via merger) and R&D pipelines favor it against rivals, influencing the ecosystem by pioneering saliva-based cancer detection and enabling global patient reach through combined offerings.[1]
NOWDx, powered by AEENA Dx's tech, is primed to lead in high-impact diagnostics with syphilis/strep launches and oncology expansions, potentially dominating POC/OTC segments via its Arkansas hub and C-suite synergies.[1] Trends like AI-enhanced assays and regulatory tailwinds for non-invasive tests will shape its path, evolving its influence from startup innovator to global healthcare disruptor serving millions.[1][2] This merger trajectory echoes AEENA Dx's core promise: transforming diagnostics from lab-bound to everyday accessible tools.
AEENA Dx has raised $48K across 1 funding round. Most recently, it raised $48K Series A in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $48K Series A | — | Ambit Health Ventures, Esplanade Healthtech Ventures, Good Growth Capital | Announced |
AEENA Dx has raised $48K in total across 1 funding round.
AEENA Dx's investors include Ambit Health Ventures, Esplanade HealthTech Ventures, Good Growth Capital.